Why There’s Still Room For Sarilumab In RA, According To Sanofi
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III TARGET data presented at the American College of Rheumatology meeting support the novel IL-6 inhibitor’s efficacy and safety in rheumatoid arthritis, but Sanofi and partner Regeneron are under pressure to differentiate the new biologic in a crowded market.
You may also be interested in...
Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017
Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.